Importer of Controlled Substances Application: Sharp Clinical Services, Inc., 16497 [2022-06161]
Download as PDF
<![CDATA[
16497
Federal Register / Vol. 87, No. 56 / Wednesday, March 23, 2022 / Notices
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
In
accordance with 21 CFR 1301.33(a), this
is notice that on February 28, 2022,
Johnson Matthey Pharmaceutical
Materials, Inc., 2003 Nolte Drive, West
Deptford, New Jersey 08066–1742,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
drug codes are authorized for this
registration.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–06159 Filed 3–22–22; 8:45 am]
BILLING CODE P
SUPPLEMENTARY INFORMATION:
Controlled substance
jspears on DSK121TN23PROD with NOTICES1
Gamma Hydroxybutyric
Acid.
Marihuana .......................
Tetrahydrocannabinols ...
Noroxymorphone ............
Difenoxin .........................
Amphetamine .................
Methamphetamine ..........
Lisdexamfetamine ..........
Methylphenidate .............
Nabilone .........................
ANPP (4-Anilino-Nphenethyl-4-piperidine).
Norfentanyl (N-phenyl-N(piperidin-4-yl)
propionamide).
Cocaine ..........................
Codeine ..........................
Dihydrocodeine ...............
Oxycodone .....................
Hydromorphone ..............
Diphenoxylate .................
Ecgonine .........................
Hydrocodone ..................
Levorphanol ....................
Meperidine ......................
Methadone ......................
Methadone intermediate
Morphine .........................
Thebaine .........................
Opium tincture ................
Oxymorphone .................
Noroxymorphone ............
Alfentanil .........................
Remifentanil ....................
Sufentanil ........................
Tapentadol ......................
Fentanyl ..........................
Drug
code
Schedule
2010
I
7360
7370
9145
9168
1100
1105
1205
1724
7379
8333
I
I
I
I
II
II
II
II
II
II
8366
II
9041
9050
9120
9143
9150
9170
9180
9193
9220
9230
9250
9254
9300
9333
9630
9652
9668
9737
9739
9740
9780
9801
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
20:07 Mar 22, 2022
Jkt 256001
Controlled substance
Drug Enforcement Administration
[Docket No. DEA–979]
Importer of Controlled Substances
Application: Sharp Clinical Services,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Sharp Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 22, 2022. Such
persons may also file a written request
for a hearing on the application on or
before April 22, 2022.
ADDRESSES: The DEA requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUMMARY:
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates or for sale to its
customers. In reference to drug codes
7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
In
accordance with 21 CFR 1301.34(a), this
is notice that on February 2, 2022, Sharp
Clinical Services, Inc. 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020–
8024, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Gamma Hydroxybutyric
Acid.
3,4Methylenedioxymethamphetamine.
Drug
code
Schedule
2010
I
7405
I
The company plans to import the
listed control substances for clinical
trials. No other activity for these drug
codes is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–06161 Filed 3–22–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–984]
Bulk Manufacturer of Controlled
Substances Application: Siemens
Healthcare Diagnostics, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Siemens Healthcare
Diagnostics, Inc. has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 23, 2022. Such persons
may also file a written request for a
hearing on the application on or before
May 23, 2022.
ADDRESSES: The Drug Enforcement
Administration (DEA) requires that all
comments be submitted electronically
SUMMARY:
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 87, Number 56 (Wednesday, March 23, 2022)]
[Notices]
[Page 16497]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-06161]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-979]
Importer of Controlled Substances Application: Sharp Clinical
Services, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sharp Clinical Services, Inc. has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
April 22, 2022. Such persons may also file a written request for a
hearing on the application on or before April 22, 2022.
ADDRESSES: The DEA requires that all comments be submitted
electronically through the Federal eRulemaking Portal, which provides
the ability to type short comments directly into the comment field on
the web page or attach a file for lengthier comments. Please go to
https://www.regulations.gov and follow the online instructions at that
site for submitting comments. Upon submission of your comment, you will
receive a Comment Tracking Number. Please be aware that submitted
comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number,
your comment has been successfully submitted and there is no need to
resubmit the same comment. All requests for a hearing must be sent to:
(1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests
for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on February 2, 2022, Sharp Clinical Services, Inc. 2400
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
3,4-Methylenedioxymethamphetamine...... 7405 I
------------------------------------------------------------------------
The company plans to import the listed control substances for
clinical trials. No other activity for these drug codes is authorized
for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022-06161 Filed 3-22-22; 8:45 am]
BILLING CODE P
